Abstract-In this study, exposure and ecotoxicity data of six human pharmaceuticals (carbamazepine, clofibric acid, diclofenac, ofloxacin, propranolol, and sulfamethoxazole) were collected, including our own experimental data and literature data. From this data collection, the two-tiered European draft guideline on the environmental risk assessment of human pharmaceuticals was tested. Measured environmental concentrations in effluents from France and in effluents and surface waters from Germany were compared to the predicted environmental concentrations (PECs) in both countries. In a similar manner, predicted no-effect concentrations (PNECs) derived from acute data and PNECs derived from chronic data were estimated for each pharmaceutical and corresponding PEC/PNEC ratios then were compared in both countries. Globally, results demonstrated that all environmental concentrations (predicted or measured) for each considered pharmaceutical exceeded the 10-ng/L cutoff value, which requires the implementation of the second-tier assessment based on ecotoxicity data. Moreover, the six pharmaceuticals showed a relatively limited acute toxicity, and carbamazepine and propranolol were inaccurately identified as having negligible risks under the current European draft procedure. Such results lead to discussion of the actual procedure on pharmaceuticals, especially on the need of appropriate ecotoxicity tests.
INTRODUCTION
Recently, pharmaceutical compounds have become an environmental concern [1] . Sewage treatment plants (STPs) were identified as the major source of environmental discharge for these compounds [2] [3] [4] . Consequently, variable quantities of pharmaceuticals can reach surface waters, groundwaters [5] , and sediments [6] , resulting in concentrations ranging from nanograms per liter to micrograms per liter [7] . Although they can be degraded in the environment by biotic or abiotic processes [8] [9] [10] , pharmaceuticals may behave as persistent compounds because of their continual infusion into aquatic media via STP effluents [2, 11] . For this reason and because of the intrinsic property of pharmaceuticals to cause a biological effect, the risk they present to the environment cannot be ruled out [12] .
Procedures for conducting environmental risk assessment (ERA) on pharmaceuticals need to be developed. At the present time, regulations are in effect or planned in countries such as the United States [13] and Canada [14] . In Europe, the procedure for an ERA of a nongenetically modified organism containing medicinal products for human use is described in a recently published discussion paper of the Committee for Proprietary Medicinal Products of the European Medicines Evaluation Agency (EMEA) (http://www.argotech.com/ products/specolumns/resin.html) [15] . In essence, this procedure follows the general principle of the ERA procedure as * To whom correspondence may be addressed (jeanne.garric@cemagref.fr).
applied to existing and new conventional chemicals in Europe [16] . Globally, the draft guideline describes a stepwise tiered procedure for the ERA (Fig. 1) . The first tier consists of deriving a crude predicted environmental concentration (PEC) in the aquatic compartment for the pharmaceutical or its major metabolites. This is accomplished by integrating information on predicted amounts used and specific removal rates in an STP or surface waters. If this crude PEC is above 10 ng/L, a crude environmental effect analysis is performed in the second tier. To do this, a predicted no-effect concentration (PNEC; the environmental level at which no adverse effect on aquatic ecosystem function is to be expected) is derived by dividing the lowest 50%-effect concentration from acute ecotoxicity tests with algae, Daphnia, or fish by an assessment factor (AF; usually 1,000). A risk quotient PEC/PNEC then is calculated. If this ratio equals or exceeds 1, an ecological risk is suspected, and further considerations on a case-by-case basis are possibly needed in a third tier to refine the PEC and the PNEC. This current European draft guideline is simple and straightforward for tiers 1 and 2, but it has also been criticized for exactly the same reason [17] . In this sense, this procedure still needs to be evaluated regarding its suitability to provide a soundly based ERA of pharmaceutical [17] .
The major objective of the present study was to test the current European ERA procedure [15] to evaluate the protective capacity of this tiered approach. Such a work has been previously performed for the 25 most commonly used pharmaceuticals in Denmark [18] and in the United Kingdom [19] , by using experimental or modeled acute toxicity data. How- Fig. 1 . Schematic decision tree for environmental risk assessment (ERA) of human pharmaceutical compounds [15, 17] : estimation of the predicted environmental concentration (PEC) of France and Germany and the predicted no-effect concentration (PNEC) from complementary data presented in this study.
ever, the particularity of our study is that chronic toxicity data also have been integrated to evaluate the EMEA procedure [15] . Briefly, we selected six widely consumed pharmaceuticals (carbamazepine, clofibric acid, diclofenac, ofloxacin, propranolol, and sulfamethoxazole) that have been found in STP effluents in several European countries [20] . From these pharmaceuticals, tiers 1 and 2 of this procedure then were evaluated as summarized in Figure 1 . First, the measured concentrations in STP effluents in France and in STP effluents and surface waters in Germany were compared to estimated PECs in both countries. To do this, the measured environmental concentrations were obtained from the literature for Germany and, for France, from our own effluent monitoring campaign. Second, PNECs derived from acute data and PNECs derived from chronic data were estimated for each pharmaceutical and corresponding PEC/PNEC ratios then were compared in both countries. For this purpose, acute and chronic data obtained from standardized tests on aquatic organisms belonging to different trophic levels were collected, from our own experimental data and literature data. The collected data set allowed establishment of further sound considerations for discussing the actual ERA procedure on pharmaceuticals, particularly in focusing on the two most delicate points of the EMEA procedure, that is, the cutoff approach and the use of acute tests to derive PNECs.
MATERIALS AND METHODS

Substances tested
Carbamazepine (antiepileptic, Chemical Abstracts Service [CAS] 298-46-4, purity Ͼ 99%), clofibric acid (lipid regulator, CAS 882-09-7, purity Ͼ 97%), diclofenac sodium (nonsteroidal anti-inflammatory, CAS 15307-79-6, purity Ͼ 99%), ofloxacin (antibiotic, CAS 82419-36-1, purity Ͼ 97%), propranolol (antihypertensive, CAS 318-98-9, purity Ͼ 97%), and sulfamethoxazole (antibiotic, CAS 723-46-6, purity Ͼ 97%) were purchased from Sigma-Aldrich (St. Quentin Fallavier, France). An overview of their most relevant characteristics and their total prescription in France and Germany is presented in Table 1 .
Occurrence in effluents and surface water of France and Germany
For Germany, the concentrations of the six pharmaceuticals in the environment were obtained from the literature. Because the available exposure data were heterogeneously presented in the literature (i.e., minimum, average, 90th percentile, or maximum), only the maximal environmental concentrations measured in effluents (MEC effl s) and in surface waters (MEC sw s), which were available in all the studies, were considered. In contrast to Germany, from the nonconfidential scientific literature, no data about the occurrence of these compounds in the aquatic environment were available for France. To partially remedy this situation, an effluent-monitoring campaign was performed on two chosen STPs in the vicinity of Lyon, the second largest city in France. The values of MEC effl obtained in this way are used in the present study. The first STP, Châ-tillon-sur-Chalaronne, situated on the Dombes plateau, northeast of Lyon, serves a population of about 6,000 and receives domestic and industrial (pharmaceutical, plastic, and metal industries) discharges. The annual treated volume is 0.5 Mm 3 with the average influent biological oxygen demand of about 120 mg O 2 /L. Water treatment includes primary settling and an activated sludge process. The effluent is discharged to the Chalaronne River. The second STP, Pierre Bénite, situated in southern Lyon where the Saône River and the Rhône River meet, serves a population of about 475,000, and receives domestic and industrial (pharmaceutical, chemical, and food-processing industries) discharges. The annual treated volume is 48 Mm 3 with the average influent biological oxygen demand of about 200 mg O 2 /L. Water treatment includes primary settling and an activated sludge process. The effluent is discharged to the Rhône River.
The sampling (24-h average flow-proportional effluent samples) was performed in February to March 2001 at both abovementioned STPs and was repeated in January 2003 at Pierre Bénite. The collected unfiltered samples were concentrated by using solid-phase extraction by two different procedures, with one using Isolut RP-C18 solid-phase extraction cartridges (IST, Hengoed, UK) for gas chromatography-mass spectrometry analysis of carbamazepine, clofibric acid, and diclofenac, and the other using Isolut C2/ENVϩ solid-phase extraction cartridges (IST) for liquid chromatography-tandem mass spectrometry analysis of ofloxacin, propranolol, and sulfamethoxazole. Concentration and analytical procedures have been previously described in detail by Andreozzi et al. [20] .
Ecotoxicity of pharmaceuticals
For the ecotoxicity portion, a comprehensive literature review of freshwater acute and chronic laboratory toxicity tests of each tested substance was conducted. For acute toxicity, all tests for which concentrations that cause 50% of effect (EC50s) on the assessment endpoint were available were reported. For chronic toxicity, the tests for which chronic no-observed-effect concentrations (NOECs) were available were used. Moreover, because of the lack of toxicity data and in order to complete the review, standardized test methods were carried out in the framework of the study for estimating acute and chronic toxicities of the six selected compounds to aquatic organisms from different trophic levels.
Briefly, the acute bioassays performed were the 30-min Microtox test (Azure Environmental, Carlsbad, CA, USA), which measures the inhibition of the bioluminescence of the bacteria Vibrio fischeri according to the standard AFNOR T90-320-3 [21] , and the Daphnia magna and Ceriodaphnia dubia 2-d tests, respectively, conducted according to the standard AFNOR T90-301 [22] and the standard EPA 600/490/027 [23] , which measure the inhibition of mobility of these two B. Ferrari et al. Amount in kg/year in Germany (1995) [40, 41] 80,000 16,000 Pharmacokinetic excretion rate [40, 41] 1-2% unchanged 90% as conjugates (from clofibrate) Total removal via STPs [40] 7% 51% [4] . Furthermore, dose-response curves from ecotoxicity tests were expressed as nominal concentrations versus the percentage of observed effect. For acute tests, EC50s were determined by regression by using a log-logistic model (Hill model) [27] . For the chronic tests, NOECs were determined by hypothesis tests. Dunnett's tests were used after verifying the ShapiroWilk's test for normality and the Hartley's test for homogeneity of variance. If unequal numbers of replicates occurred among the concentration levels tested, a t test with Bonferroni adjustment was used [4, 27] .
In addition, to assess effects on phytoplankton community, three algal growth inhibition tests were performed against each of the pharmaceuticals with the standard green alga Pseudokirchneriella subcapitata (strain UTEX 1648), the diatom Cyclotella meneghiniana (strain SAG 1020-1a), and the bluegreen alga Synechococcus leopolensis (strain UTEX 625). Inocula, corresponding to 10,000 or 100,000 cells/ml from our laboratory cultures in midexponential phase, were grown in 100-ml conical flasks containing Bold's basal medium for P. subcapitata and S. leopolensis, and Bacillariophyta medium for C. meneghiniana. All tests were carried out in triplicate in axenic conditions at 23 Ϯ 1ЊC for P. subcapitata and at 28 Ϯ 1ЊC for C. meneghiniana and S. leopolensis, with lighting of 8,300 lux under a 16:8 h light:dark photoperiod. After 96 h of incubation, algal growth was followed either by counting the cell number with a Burker bloodcounting chamber (Fortuna, Wertheim, Germany) or by measuring the absorbance increase at 550 nm with a colorimeter (Bausch & Lomb spectronic 20, Rochester, NY, USA). In each bioassay, the relative EC50s were used as acute measured endpoints and calculated as described previously. Moreover, chronic NOECs also were determined. Indeed, as it is noticed in the technical guidance document in Europe [16] , in the case of algae studies, it is generally accepted that a 96-h EC50 value may be considered as equivalent to a short-term result and that a 96-h NOEC value may be considered as a long-term result. However, algal NOECs would not be used unsupported by other long-term data.
PEC and PNEC extrapolation methods
Crude PEC values were calculated from the simple Equation 1 for France and Germany according to the EMEA procedure [15] A ϫ (100 Ϫ R)
where A is the amount used per year (in kg/year), R is the removal rate in percent, P is the number of inhabitants in the geographic area considered, V is the volume of wastewater per day per capita (in m 3 ) in the considered country, D is the dilution factor of wastewater by surface water flow, and 100 is the conversion factor for percentage. This calculation of crude PECs assumed that the amount used per year was evenly distributed over the year, all six pharmaceuticals were used evenly throughout the geographic areas considered, and STPs were the main points of entry to the environment for these six pharmaceuticals. In addition to these, a worst-case scenario was assumed with no human metabolism and no degradation or adsorption (R ϭ 0). Moreover, PECs were calculated with an average 10-fold dilution (D ϭ 10) of effluent in surface water (PEC sw ) and with no dilution (D ϭ 1) corresponding to PECs in effluents (PEC effl ). For France, the calculation was based on the quantities reported in this country in 1999 (Table  1 ) with a population of 61 million and an average wastewater production of 150 L per person per day. For Germany, the calculation was based on the quantities reported in this country in 1995 (Table 1 ) with a population 81.3 million and an average wastewater production of 140 L per person per day [12] . The AF approach was used to generate PNECs from toxicity test results. These AFs are generally used to add a margin of safety to a toxicological endpoint, thereby establishing an environmental concentration below which no adverse impact to the aquatic biota is expected (i.e., PNEC). For each pharmaceutical, two extrapolation methods were carried out with only the toxicity data from algae, invertebrates, and fish reported in this study. First, a PNEC derived from the reported acute test results (PNEC acute ) was calculated by dividing the lowest EC50 value obtained with an AF of 1,000, as recommended in tier 2 of the EMEA procedure [15] . Second, a PNEC derived from the reported chronic test results (PNEC chronic ) also was calculated by dividing the lowest NOEC value obtained with an AF of 10 or 50, depending of the quality of the data as recommended in the technical guidance document [16] .
RESULTS AND DISCUSSION
The most important element of any preliminary ERA approach purporting to identify chemicals that pose a negligible risk for the environment is that the risk of having false-negative errors is minimal and acceptable. A false-negative error is one where a chemical that represents significant risks to the environment is inaccurately identified as having negligible risks [28] . In this sense, the EMEA procedure for pharmaceutical ERAs in Europe [15] must not represent the exception and should include an appropriate level of precaution to avoid false-negative errors. To examine the protective capacity of this tiered procedure, we tested tiers 1 and 2 by using experimental and literature data obtained for carbamazepine, clofibric acid, diclofenac, ofloxacin, propranolol, and sulfamethoxazole (see Fig. 1 ).
Evaluation of tier 1: Comparison of the PEC with the environmental concentrations of the six pharmaceuticals and the cutoff value
The initial step of ERA aims to estimate the environmental concentration in the aquatic compartment receiving the discharge of STPs. In most cases, the crude PEC sw is calculated as defined in Equation 1 within the worst-case scenario, with R ϭ 0 and D ϭ 10 [18, 19] . Then, the calculated crude PEC sw is compared to the 0.01 g/L cutoff value that requires a tier 2 assessment to be conducted according the EMEA procedure [15] . Table 1 shows the available data on production and reveals that the six compounds studied are used in quantities greater than 10 tons per year per country, except for ofloxacin in France and propranolol in Germany. These figures most likely underestimate the total active compound because they do not include drugs acquired over the counter. More, some difference of production is apparent between France and Germany for each compound. This may reflect the different therapeutic practices in each country and influence the PEC estimation. Table 2 establishes the presence and the maximal concentration levels of the six studied pharmaceuticals in treated wastewater (MEC effl ) and rivers (MEC sw ). For the literature review, only references that presented data corresponding to a MEC were considered. Moreover, where multiple MECs were available for the same compound in the same reference, only the greatest value was included in the [15] in relation to the pharmaceutical amount used per year in each country (see Table 1 ).
and surface water in the nanogram per liter to microgram per liter range [2, 3, 7, 11] . These measured MECs can easily be compared to those predicted (i.e., PEC effl and PEC sw ) for both countries considered in this study. Figure 2a summarizes for each compound found in France the highest MEC effl reported in Table 2 PEC sw was overestimated. On the contrary, for clofibric acid and propranolol, PEC sw was underestimated (i.e., PEC sw Ͻ MEC sw ), although the total removal via STP of these two compounds exceeded 50%, as shown in Table 1 . Finally, the PEC sw calculated for carbamazepine was very similar to the MEC sw . According to the different worst-case assumptions used for the PEC calculations in this study, overestimation of the PEC sw indicates that relevant elimination processes were not considered in the calculation or that dilution (D ϭ 10) in surface water must be refined. However, this uncertainty on the PEC sw estimation has no consequence on the protective capacity of the EMEA procedure [15] . In fact, because the PEC sw is used to calculate the risk ratio, its overestimation leads to decrease the probability of false-negative errors in tier 2 of the ERA procedure. In contrast, underestimation of the PEC sw , which indicates that relevant sources of emission are neglected, leads to an increase in the probability of having false-negative errors in tier 2 and, thus, decreases the protective capacity of the initial ERA procedure. In order to accurately predict the PEC sw , the next steps in the risk assessment process must be to refine the input data for human metabolism, biotic and abiotic degradation in STP and surface water, and the variations over time in the concentration, and finally the load in effluents and surface water of pharmaceuticals [11, 29] . Other models taking into account in an integrated manner information on use and fate, such as the GREAT-ER model, or the EUSES model (European Chemicals Bureau, Ispra, Italy) already used in support of existing substances regulation [16] , also could be profitably applied for PEC sw estimation [29] . Nevertheless, and probably the most important, all environmental concentrations (predicted or measured) for each considered pharmaceutical were at least of an order of magnitude higher than the 10-ng/ L cutoff value. These results lead in any case to implementation of the tier 2 assessment of the EMEA procedure [15] .
Comparison of the tier 1 cutoff value with ecotoxicity of the six pharmaceuticals
Within this study, available acute and chronic data for aquatic organisms were secured for the six pharmaceuticals tested. Globally, 53 acute EC50 data points on 15 different species (Table 3 ) and 41 chronic NOEC data points on nine species (Table 4) are available. The results displayed here possibly represent the most comprehensive data set yet collated for the six compounds. In both acute and chronic data sets, a minimum of three trophic levels per pharmaceutical were investigated, corresponding mainly to acute tests on microorganisms, algae, and invertebrates and chronic tests on algae, invertebrates, and fish. Furthermore, the number of species used per trophic level did not exceed three, except for propranolol, which was tested on six different invertebrates for acute tests.
Of the 94 toxicity data points presented, the range of reported acute EC50 values varied from Ͼ200 mg/L for clofibric acid (ceriodaphnid and daphnid tests) down to 10 g/L for ofloxacin (bacteria tests), whereas chronic NOEC values varied from Ͼ100 mg/L for carbamazepine (green algae tests) and for clofibric acid (diatom tests) down to 0.5 g/L for propranolol (fish test). Based on these two data sets, acute and chronic distributions of sensitivities of aquatic species to the six pharmaceuticals were compared in a more integrated approach. To do this, acute EC50 data for all species and all pharmaceuticals were combined and ranked by concentrations in increasing order and for each value the percentile ranking was calculated as n/(N ϩ 1), where n is the rank for the considered value and N is the total number of values. This calculation was repeated for the chronic NOEC data set. Each percentile obtained for the acute and chronic data sets then was plotted as a function of the log 10 -transformed concentration (Fig. 3) , and a best-fit nonlinear regression (Weibull model) was applied to predict each distribution by using SigmaPlot [30] .
Assuming a good-fit nonlinear regression when using the Weibull model for each acute and chronic toxicity distribution (i.e., r 2 ഠ 0.98), it is acceptable to estimate a global hazardous concentration for 5% of species (HC5), defined as the concentration below which none of the six pharmaceuticals tested is likely to cause unacceptable effects on 95% of the species present in a community. As presented in Figure 3 , where HC5 is determined as the fifth percentile of sensitivity, the acute HC5 would correspond to 93.3 g/L whereas the chronic HC5 would correspond to 0.35 g/L. Assuming that the HC5 is an acceptable level to minimize environmental risk [31] , in this study the use of the cutoff value of 0.01 g/L in tier 1 as the criterion for carrying out the second-tier assessment based on ecotoxicity data (see Fig. 1 ) seems reliable. Indeed, this cutoff is 35 times lower than the chronic HC5 and, thus, appears sufficiently protective for the aquatic ecosystem. Nevertheless, this conclusion is based only on the toxicity data of the six tested pharmaceuticals. This is likely to change drastically if compounds such as estrogens are considered because of their possible potency in terms of chronic ecotoxicity at concentrations less than 10 ng/L, as was demonstrated with a fish reproduction test [32] . Even more important, the knowledge about joint toxicity of multicomponent pharmaceutical mixtures (i.e., independent, additive, antagonistic, or synergistic interactions) should be integrated, as demonstrated for similar acting compounds such as antibiotics [33] or estrogens [34, 35] . Therefore, the use of such an approach based on concentration action limits still needs to be soundly validated for a greater number of pharmaceuticals.
Comparison of acute ecotoxicity testing with chronic ecotoxicity testing
Not surprisingly, variations of toxicity of all the six pharmaceuticals depicted in Figure 3 show that chronic tests display higher toxicity than acute tests. For example, the predicted acute toxicity distribution (r 2 ϭ 0.975) reveals that a concentration of 1 mg/L would affect only 15% of species compared to 45% of species when using predicted chronic toxicity distribution (r 2 ϭ 0.983). Similarly, Webb [32] reported, in a review revealing more than 360 acute measured endpoints in algae, invertebrates, and fish for 107 pharmaceuticals, that 100% of the toxicological results were at concentrations higher than 1 g/L, but only 10% were at concentrations less than 1 mg/L. These observations emphasize that the majority of the pharmaceuticals examined are limited in their acute ecotoxicity. Regarding the maximal levels at which the six pharmaceuticals are found in effluents or surface water (i.e., Table  2 ) and the levels of PEC effl and PEC sw calculated in worst-case situations (i.e., Fig. 2a and b) , the highest maximum concentration did not exceed 19 g/L (i.e., German PEC effl for carbamazepine). This is four times less than the acute HC5, but in contrast, 54 times higher than the chronic HC5. Consequently, because of their low but persistent occurrence in the environment, pharmaceuticals will most likely have chronic rather than acute ecotoxic effects [19] . Such a comparison B. Ferrari et al. highlights that standardized acute bioassays are not the most appropriate basis for the ecotoxicological hazard assessment of pharmaceuticals, and that chronic bioassays performed on different organisms should be implemented to estimate a best level of protection in risk assessment of pharmaceuticals.
Evaluation of tier 2: Comparison of the PNEC acute with the PNEC chronic and calculation of the risk ratios
The second step in the prioritization process is to estimate the potential risk of pharmaceuticals in the aquatic environment by calculating the ratio PEC sw /PNEC. Normally, as recommended in tier 2 of the EMEA procedure presented in this study (Fig. 1) , PNECs used to predict concentrations of substances for which adverse effects are not expected to occur in the aquatic compartment are derived from results based on standardized acute toxicity tests performed on several test organisms (i.e., algae, daphnids, and fish).
The preliminary estimation of the aquatic risk in France and Germany for the six pharmaceuticals is detailed in Table  5 . In any case, if the exposure concentration equals or exceeds the effect concentration (PEC sw /PNEC (acute or chronic) Ն 1), then an ecological risk is suspected. The PEC sw corresponded to those calculated for France and Germany in Figure 2a and b, respectively. For each pharmaceutical, the PNEC acute was derived by using an AF of 1,000 applied to the lowest EC50 from algal, invertebrate, and fish toxicity studies reported in Table 3 , as recommended in tier 2 of the EMEA procedure [15] . The PNEC chronic also was calculated for each pharmaceutical by dividing the lowest NOEC value from algal, invertebrate, and fish toxicity studies reported in Table 4 with an AF of 10 or 50, depending of the quality of the data as recommended in the technical guidance document [16] . Regarding all available acute EC50 and chronic NOEC, blue-green algae were considered as the most sensitive organisms in acute tests for clofibric acid and diclofenac and diatoms were most sensitive for carbamazepine and propranolol. In chronic tests, crustaceans were considered as the most sensitive organisms for carbamazepine and diclofenac, rotifers as most sensitive for clofibric acid, and fish as most sensitive for propranolol. Because the most sensitive species are different according to acute or chronic test results, PNEC chronic values for these four compounds were estimated by applying an AF of 50. In contrast, because ofloxacin and sulfamethoxazole were quite toxic to blue-green algae in both acute and chronic tests compared to the other tested organisms, the PNEC chronic for these tow antibiotics were estimated by applying an AF of 10. It is interesting to notice the strong effects of these two antibiotics upon algae and in particular cyanobacteria in comparison to higher organisms. These observations should not come as a surprise because algae are phylogenetically much closer to the pathogenic bacteria than to organisms of higher phylogenetic classes such as crustaceans and fish [36] .
Compared to the PNEC chronic , PNEC acute values calculated for diclofenac, ofloxacin, and sulfamethoxazole were lower, whereas they were higher for carbamazepine, clofibric acid, and propranolol (Table 5 ). These observations have some consequences on the ERA conclusions based only on the calculation of the ratio PEC sw /PNEC acute to estimate the potential risk of pharmaceuticals in the aquatic environment in tier 2 of the EMEA procedure (Fig. 1) . Indeed, PEC sw /PNEC chronic compared to PEC sw /PNEC acute calculated for each compound (Table  5) revealed that carbamazepine was inaccurately identified as having negligible risk in France and Germany. Furthermore, propranolol also was inaccurately identified as having negligible risk in Germany, and this result is reinforced by the fact that the German PEC sw calculated for this compound may be underestimated when compared to the German MEC sw (i.e., Fig. 2b ). It also can be stressed that carbamazepine is found to be quite persistent in the aquatic environment [11, 20] and that propranolol, with a log 10 -transformed octanol-water partition coefficient (log K OW ) of 3.5 (see Table 1 ), is potentially able to bioaccumulate. Therefore, such pharmaceuticals are likely to exert long-term effects, which cannot be detected when using short exposure. For all these considerations, such results demonstrate that the applicability of standardized acute tests are definitively not relevant to predict pharmaceuticals that will pose a risk for the aquatic environment when they are carried out in the framework of the preliminary pharmaceutical ERA scheme tested in this study (Fig. 1) .
Further recommendations for an improvement of tier 2
In addition to the fact that the PEC sw should be refined for a better risk ratio characterization as previously described, some other aspects should be explored to reduce some of the uncertainty in the preliminary pharmaceutical ERA scheme tested in this study (Fig. 1) . They could be profitably used to improve the tier 2 assessment.
For example, the pharmaceutical ERA procedure developed in the United States by the Food and Drug Administration (FDA) [13] presents some advantages compared to the EMEA procedure [15] evaluated in the study. First, and probably the most important, the FDA guidance includes chronic toxicity tests that, in this study, have proved to be more suitable to identify environmental hazardous pharmaceuticals. Second, this FDA procedure focuses on the assessment of the pharmaceutical potential to inhibit microorganisms and subsequently to disrupt waste treatment processes as an initial step of the ERA. In other terms, if no rapid, complete depletion mechanism has been identified, it should be assumed that the pharmaceutical will persist in the environment for some time and, therefore, the toxicity of the released substance toward environmental organisms should be evaluated. Third, the FDA procedure focuses on the maximal expected environmental concentration of the pharmaceutical, which corresponds to the highest concentration between the PEC effl or the PEC sw . Consequently, the FDA procedure leads to a higher level of protection than the EMEA procedure [15] . And finally, the FDA procedure takes into account the potential of pharmaceuticals to bioaccumulate or bioconcentrate in order to identify as early as possible the compounds that are candidates for chronic toxicity testing. For this purpose, a log K OW limit of 3.5, above which the chronic toxicity testing is directly initiated, is recommended. For example, with a log K OW of 3.5 (see Table 1 ), propranolol would have been directly tested with chronic tests and, thus, avoided false-negative error obtained when using the EMEA guidance [15] . Nevertheless, even if the FDA pro-cedure [13] has some advantages compared to the EMEA procedure, pharmaceuticals considered as persistent with a log K OW below 3.5 are tested first with standardized acute tests, which are not suitable for an initial ERA as shown in this study.
Although the use of chronic toxicity tests with several species would be ideal for performing ERA for every pharmaceutical, it is not realistic to expect such an experimental effort because of both time and financial constraints. Therefore, the use of standardized acute tests, combined with a protective AF, cannot be ignored for the assessment of the intrinsic ecotoxicological properties of pharmaceuticals. However, applying a maximal AF of 1,000 on acute data to protect the ecosystem from adverse effect of chemicals is questionable [37] . From the reported data in this study, acute EC50s (Table 3) and chronic NOECs (Table 4) were available for ceriodaphnids and fish for the six pharmaceuticals. Based on these data, the acute to chronic ratio ranged from 23 to 3,000 for the crustacean C. dubia exposed to diclofenac and carbamazepine, respectively, to 48,600 for the fish Oryzias latipes exposed to propranolol. Furthermore, in chronic tests and for propranolol one can observe that O. latipes was 250 times more sensitive than C. dubia. Consequently, use of a maximal AF of 1,000 is obviously not sufficient to take into account the variability in toxicity due to the quality of the pharmaceutical and the variability within and among species. For this reason, it would be advisable to increase this AF when only acute data from standardized tests are available in order to cover each of the uncertainties arising from the extrapolation from the laboratory tests to the ecosystem. However, on the basis of the limited data set used, it is obviously not realistic to propose a new AF from this study.
Additionally, and because pharmaceuticals are designed with the intention of exerting a biological effect [12] , research is necessary to reduce some of the uncertainty in the tier 2 assessment by accounting for the mode of action of pharmaceuticals. For example, Länge and Dietrich [36] proposed an interesting case-by-case testing strategy starting with a preevaluation based on the mode of action of the pharmaceutical in question. This preevaluation makes use of pharmacological and toxicological information as well as pharmacokinetic and toxicokinetic information derived from mammals during drug development, in combination with short-term ecotoxicological information. This approach should support better decisions in the selection of candidate pharmaceuticals for long-term effects studies and for the identification of the most suitable species, test system, test duration, and relevant endpoints to monitor. In this sense, it is essential to develop specific new endpoints related to the known mode of action of pharmaceuticals to improve the suitability of the acute ecotoxicity testing. This could be achieved by developing new or modified shortterm aquatic toxicity tests to obtain easy and quick preliminary results of specific effects [38] . Additionally, in vitro biomarkers related to the mechanisms of toxicity could be usefully developed to screen the mode of action of pharmaceuticals [39] . However, efforts also will be necessary to soundly validate the tests as early warning indicators for the potential long-term harm of the pharmaceuticals by comparison with chronic effect studies.
CONCLUSION
In this investigation, the two-tiered European draft guideline on the environmental risk assessment of human pharmaceuticals [15] was tested against experimental measurements for exposure and toxicity obtained for carbamazepine, clofibric acid, diclofenac, ofloxacin, propranolol, and sulfamethoxazole. For the tier 1 assessment part of the guideline, comparison between predicted and measured environmental concentrations in France and Germany for the six pharmaceuticals investigated has shown that in most cases, values were not different at more than one order of magnitude. Nevertheless, even if some differences exist, all environmental concentrations (predicted or measured) for each considered pharmaceutical were at least of an order of magnitude higher than the 10-ng/L cutoff value. This result leads to implement the second tier assessment based on ecotoxicity data according to the proposed guidance [15] . In addition, comparison of the 10-ng/L cutoff value with the ecotoxicity of the six pharmaceuticals demonstrated that this trigger value is reliable for the six compounds tested, but such an approach based on concentration action limits still needs to be soundly validated. For the tier 2 assessment part of the guideline, comparison between acute and chronic effects of the six pharmaceuticals highlighted that standardized acute tests were not the most appropriate basis for ecotoxicological hazard assessment of pharmaceuticals. Two pharmaceuticals (i.e., carbamazepine and propranolol) among the six tested were inaccurately identified as having negligible risks when using the PEC/PNEC proposed approach.
For all these considerations, results refute rather than substantiate the fact that the pharmaceutical ERA procedure tested in this study is sufficient for the protection of the aquatic environment. Among different keys for a proper pharmaceutical ERA, chronic effect studies are more than adequate. Additionally, efforts are necessary to reduce the uncertainty related to the use of AF when only acute data are available. Finally, the development of new endpoints related to the known mode of action of pharmaceuticals should improve the suitability of the acute ecotoxicity testing.
